Hirotsu Bio Science
Tokyo, Japan· Est.
Develops non-invasive cancer screening tests using nematodes' olfactory sensors combined with AI for early detection.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Develops non-invasive cancer screening tests using nematodes' olfactory sensors combined with AI for early detection.
Oncology
Technology Platform
Uses nematodes (C. elegans) with highly sensitive olfactory receptors to detect cancer-specific odor biomarkers in urine samples, combined with AI/machine learning for pattern recognition.
Opportunities
Expansion of N-NOSE test to international markets, particularly North America, and development of additional diagnostic applications using their nematode-AI platform for other diseases.
Risk Factors
Clinical validation and regulatory acceptance of nematode-based diagnostics in major markets, competition from established liquid biopsy and imaging technologies, and scalability of biological testing processes.
Competitive Landscape
Competes with conventional cancer screening methods (imaging, blood tests) and emerging liquid biopsy companies like Grail, Guardant Health, and Exact Sciences, but differentiates through unique biological detection mechanism using nematodes.